Rationale, Design, and Baseline Characteristics of a Trial Comparing Aggressive Lipid Lowering With Atorvastatin Versus Revascularization Treatments (AVERT) fn1fn1This work is supported by a grant from Parke-Davis Pharmaceutical Research, a Division of Warner-Lambert Company, Ann Arbor, Michigan.